Camurus AB (publ) (LON:0RD1)
694.00
+2.50 (0.36%)
At close: Sep 18, 2025
Camurus AB Employees
Camurus AB had 256 employees as of December 31, 2024. The number of employees increased by 43 or 20.19% compared to the previous year.
Employees
256
Change (1Y)
43
Growth (1Y)
20.19%
Revenue / Employee
651.58K GBP
Profits / Employee
206.51K GBP
Market Cap
3.26B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 256 | 43 | 20.19% |
Dec 31, 2023 | 213 | 37 | 21.02% |
Dec 31, 2022 | 176 | 28 | 18.92% |
Dec 31, 2021 | 148 | 14 | 10.45% |
Dec 31, 2020 | 134 | 14 | 11.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Camurus AB News
- 3 months ago - Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients - PRNewsWire
- 3 months ago - Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins - PRNewsWire
- 5 months ago - CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU - PRNewsWire
- 11 months ago - US FDA declines to approve Camurus' rare hormone disorder drug - Reuters
- 1 year ago - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl - PRNewsWire